34
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Unrestricted somatic stem cells: interaction with CD34+ cells in vitro and in vivo, expression of homing genes and exclusion of tumorigenic potential

, , , , , , , , & show all
Pages 357-365 | Received 28 May 2010, Accepted 08 Sep 2010, Published online: 18 Oct 2010
 

Abstract

Background aims. Transplantation of allogeneic hematopoietic stem cells (HSC) within the framework of hematologic oncology or inherited diseases may be associated with complications such as engraftment failure and long-term pancytopenia. HSC engraftment can be improved, for example by co-transplantation with mesenchymal stem cells (MSC). Recently, a new multipotent MSC line from umbilical cord blood, unrestricted somatic stem cells (USSC), has been described. It was demonstrated that USSC significantly support proliferation of HSC in an in vitro feeder layer assay. Methods. A NOD/SCID mouse model was used to assess the effect of USSC on co-transplanted CD34+ cells and look for the fate of transplanted USSC. The migration potential of USSC was studied in a Boyden chamber migration assay and in vivo. Quantitative real-time polymerase chain reaction (qRT-PCR) for CXCR4, CD44, LFA1, CD62L, VLA4, RAC2, VLA5A and RAC1 were performed. NMR1 nu/nu mice were used for a tumorigenicity test. Results. After 4 weeks, homing of human cells (CD45+) to the bone marrow of NOD/SCID mice was significantly increased in mice co-transplanted with CD34+ cells and USSC (median 30.9%, range 7–50%) compared with the CD34+ cell-only control group (median 5.9%, range 3–10%; P = 0.004). Homing of USSC could not be shown in the bone marrow. A cell–cell contact was not required for the graft enhancing effect of USSC. An in vivo tumorigenicity assay showed no tumorigenic potential of USSC. Conclusions. This pre-clinical study clearly shows that USSC have an enhancing effect on engraftment of human CD34+ cells. USSC are a safe graft adjunct.

Acknowledgments

This work was supported by grants from the German José Carreras Leukemia Foundation (DJCLS R 07/05v), the DFG (KO 2119/6-1), the Irmgard and Udo Kahrau Foundation and the Prof. Dr. Karl and Gerhard Schiller Foundation and the Deutsche Krebshilfe/Dr Mildred-Scheel-Stiftung (10-2089- FI 1). We thank Bernhard Berkus, Hans-Jürgen Engel, Sigrid Heil and Aurélie Lefort for excellent technical assistance and Manuela Zucknick for statistical analysis of the mouse experiments.

Conflict of interest: none.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.